China Resources Boya Bio pharmaceutical Group Co Ltd (300294) - Net Assets
Based on the latest financial reports, China Resources Boya Bio pharmaceutical Group Co Ltd (300294) has net assets worth CN¥7.46 Billion CNY (≈ $1.09 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥8.41 Billion ≈ $1.23 Billion USD) and total liabilities (CN¥942.80 Million ≈ $137.96 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 300294 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥7.46 Billion |
| % of Total Assets | 88.78% |
| Annual Growth Rate | 32.33% |
| 5-Year Change | 7.86% |
| 10-Year Change | 250.09% |
| Growth Volatility | 55.38 |
China Resources Boya Bio pharmaceutical Group Co Ltd - Net Assets Trend (2008–2025)
This chart illustrates how China Resources Boya Bio pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. See China Resources Boya Bio pharmaceutical liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for China Resources Boya Bio pharmaceutical Group Co Ltd (2008–2025)
The table below shows the annual net assets of China Resources Boya Bio pharmaceutical Group Co Ltd from 2008 to 2025. For live valuation and market cap data, see how much is China Resources Boya Bio pharmaceutical worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥7.46 Billion ≈ $1.09 Billion |
-0.31% |
| 2024-12-31 | CN¥7.49 Billion ≈ $1.10 Billion |
+2.28% |
| 2023-12-31 | CN¥7.32 Billion ≈ $1.07 Billion |
+0.49% |
| 2022-12-31 | CN¥7.28 Billion ≈ $1.07 Billion |
+5.26% |
| 2021-12-31 | CN¥6.92 Billion ≈ $1.01 Billion |
+65.07% |
| 2020-12-31 | CN¥4.19 Billion ≈ $613.49 Million |
+5.11% |
| 2019-12-31 | CN¥3.99 Billion ≈ $583.66 Million |
+5.78% |
| 2018-12-31 | CN¥3.77 Billion ≈ $551.75 Million |
+51.77% |
| 2017-12-31 | CN¥2.48 Billion ≈ $363.53 Million |
+16.51% |
| 2016-12-31 | CN¥2.13 Billion ≈ $312.01 Million |
+11.74% |
| 2015-12-31 | CN¥1.91 Billion ≈ $279.22 Million |
+106.52% |
| 2014-12-31 | CN¥923.93 Million ≈ $135.20 Million |
+9.13% |
| 2013-12-31 | CN¥846.62 Million ≈ $123.89 Million |
+12.64% |
| 2012-12-31 | CN¥751.60 Million ≈ $109.98 Million |
+186.14% |
| 2011-12-31 | CN¥262.67 Million ≈ $38.44 Million |
+33.04% |
| 2010-12-31 | CN¥197.44 Million ≈ $28.89 Million |
+20.03% |
| 2009-12-31 | CN¥164.49 Million ≈ $24.07 Million |
+157.87% |
| 2008-12-31 | CN¥63.79 Million ≈ $9.33 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to China Resources Boya Bio pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 29486.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.62 Billion | 35.25% |
| Common Stock | CN¥504.25 Million | 6.78% |
| Other Comprehensive Income | CN¥252.44 Million | 3.39% |
| Other Components | CN¥4.06 Billion | 54.58% |
| Total Equity | CN¥7.44 Billion | 100.00% |
China Resources Boya Bio pharmaceutical Group Co Ltd Competitors by Market Cap
The table below lists competitors of China Resources Boya Bio pharmaceutical Group Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TRUSTPILOT GROUP LS -01
F:6VZ
|
$1.16 Billion |
|
British American Tobacco PLC
LSE:BATS
|
$1.16 Billion |
|
Bangkok Airways Public Company Limited
BK:BA
|
$1.16 Billion |
|
HHC Changzhou Corp.
SHE:301061
|
$1.16 Billion |
|
Stepan Company
NYSE:SCL
|
$1.16 Billion |
|
Chicony Power Technology Co Ltd
TW:6412
|
$1.16 Billion |
|
Ramkrishna Forgings Limited
NSE:RKFORGE
|
$1.16 Billion |
|
BrightView Holdings
NYSE:BV
|
$1.16 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in China Resources Boya Bio pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,487,150,950 to 7,437,646,428, a change of -49,504,522 (-0.7%).
- Net income of 112,698,348 contributed positively to equity growth.
- Dividend payments of 156,317,108 reduced retained earnings.
- Other comprehensive income decreased equity by 5,885,761.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥112.70 Million | +1.52% |
| Dividends Paid | CN¥156.32 Million | -2.1% |
| Other Comprehensive Income | CN¥-5.89 Million | -0.08% |
| Other Changes | CN¥-1.00 | -0.0% |
| Total Change | CN¥- | -0.66% |
Book Value vs Market Value Analysis
This analysis compares China Resources Boya Bio pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.06x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 49.98x to 1.06x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | CN¥0.31 | CN¥15.68 | x |
| 2009-12-31 | CN¥0.75 | CN¥15.68 | x |
| 2010-12-31 | CN¥0.77 | CN¥15.68 | x |
| 2011-12-31 | CN¥1.03 | CN¥15.68 | x |
| 2012-12-31 | CN¥2.36 | CN¥15.68 | x |
| 2013-12-31 | CN¥2.33 | CN¥15.68 | x |
| 2014-12-31 | CN¥2.53 | CN¥15.68 | x |
| 2015-12-31 | CN¥5.43 | CN¥15.68 | x |
| 2016-12-31 | CN¥7.85 | CN¥15.68 | x |
| 2017-12-31 | CN¥6.05 | CN¥15.68 | x |
| 2018-12-31 | CN¥8.76 | CN¥15.68 | x |
| 2019-12-31 | CN¥9.18 | CN¥15.68 | x |
| 2020-12-31 | CN¥9.64 | CN¥15.68 | x |
| 2021-12-31 | CN¥15.66 | CN¥15.68 | x |
| 2022-12-31 | CN¥14.25 | CN¥15.68 | x |
| 2023-12-31 | CN¥14.49 | CN¥15.68 | x |
| 2024-12-31 | CN¥14.85 | CN¥15.68 | x |
| 2025-12-31 | CN¥14.75 | CN¥15.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently China Resources Boya Bio pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.50%
- • Asset Turnover: 0.24x
- • Equity Multiplier: 1.16x
- Recent ROE (1.52%) is below the historical average (11.42%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 17.00% | 11.88% | 0.60x | 2.37x | CN¥4.41 Million |
| 2009 | 19.14% | 26.29% | 0.38x | 1.92x | CN¥15.03 Million |
| 2010 | 25.31% | 35.24% | 0.48x | 1.50x | CN¥30.23 Million |
| 2011 | 24.83% | 33.41% | 0.59x | 1.26x | CN¥38.97 Million |
| 2012 | 10.00% | 33.07% | 0.29x | 1.03x | CN¥-14.18K |
| 2013 | 10.40% | 33.60% | 0.24x | 1.27x | CN¥3.19 Million |
| 2014 | 12.14% | 23.80% | 0.43x | 1.19x | CN¥18.34 Million |
| 2015 | 8.10% | 27.95% | 0.25x | 1.17x | CN¥-35.68 Million |
| 2016 | 13.00% | 28.74% | 0.39x | 1.16x | CN¥62.70 Million |
| 2017 | 14.70% | 25.65% | 0.38x | 1.51x | CN¥114.01 Million |
| 2018 | 12.66% | 19.65% | 0.47x | 1.37x | CN¥98.71 Million |
| 2019 | 10.89% | 14.65% | 0.55x | 1.34x | CN¥34.97 Million |
| 2020 | 6.33% | 10.35% | 0.49x | 1.26x | CN¥-150.73 Million |
| 2021 | 5.05% | 13.00% | 0.35x | 1.12x | CN¥-338.38 Million |
| 2022 | 6.01% | 15.67% | 0.34x | 1.12x | CN¥-286.37 Million |
| 2023 | 3.24% | 8.95% | 0.34x | 1.07x | CN¥-494.51 Million |
| 2024 | 5.30% | 22.88% | 0.21x | 1.12x | CN¥-351.72 Million |
| 2025 | 1.52% | 5.50% | 0.24x | 1.16x | CN¥-631.07 Million |
Industry Comparison
This section compares China Resources Boya Bio pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $5,212,589,599
- Average return on equity (ROE) among peers: 2.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| China Resources Boya Bio pharmaceutical Group Co Ltd (300294) | CN¥7.46 Billion | 17.00% | 0.13x | $1.16 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $1.40 Billion | -0.26% | 0.06x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $966.91 Million | 19.23% | 0.71x | $1.50 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $128.43 Million | -28.90% | 2.15x | $378.62 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $512.78 Million | -14.68% | 0.29x | $470.05 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $1.54 Billion |
| Hualan Biological EngineeringInc (002007) | $13.85 Billion | 7.86% | 0.18x | $3.43 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $428.60 Million | 11.05% | 0.37x | $1.14 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $29.65 Billion | 6.00% | 0.08x | $4.52 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.45 Billion | 1.65% | 0.22x | $496.75 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $2.05 Billion | 15.59% | 0.13x | $1.64 Billion |
About China Resources Boya Bio pharmaceutical Group Co Ltd
China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the research, development, production, and sale of blood products in China. It offers blood products, such as human serum albumin; human, intravenous, freeze-dried intravenous, hepatitis B, tetanus, and rabies immunoglobulin; and human fibrinogen, prothrombin complex, and coagulation factor VIII. The company also provides compound b… Read more